MOHAMMAD NADEEM KHAN,
- Assistant Professor, Department of Pharmacology, Clinical Pharmacology, SAMC and PGI, Sri Aurobindo University, Indore, Madhya Pradesh, India
Abstract document.addEventListener(‘DOMContentLoaded’,function(){frmFrontForm.scrollToID(‘frm_container_abs_113793’);});Edit Abstract & Keyword
Non-enzymatic glycation, a biochemical process by which reducing sugars spontaneously bind to proteins, leads to the formation of advanced glycation end-products (AGEs), which have emerged as critical contributors to the pathogenesis of several neurodegenerative diseases, particularly Alzheimer’s disease (AD) and Parkinson’s disease (PD). The accumulation of AGEs can significantly alter protein structure, stability, and function, triggering a cascade of detrimental effects, including increased oxidative stress, heightened neuroinflammation, and the promotion of pathological protein aggregation—hallmarks associated with the progression of these debilitating disorders. This article delves into recent molecular and mechanistic insights into how glycation drives proteomic alterations in AD and PD, examining its impact on neuronal integrity and cellular homeostasis. Additionally, it highlights significant advancements in modern analytical techniques, such as mass spectrometry and advanced proteomic tools, that have been pivotal in elucidating glycation-induced modifications at the molecular level. Particular emphasis is placed on emerging therapeutic strategies aimed at targeting glycation pathways, including the inhibition of AGE formation, scavenging of reactive intermediates, and the enhancement of cellular repair mechanisms, offering promising avenues for innovative and effective intervention in these neurodegenerative diseases.
Keywords: Advanced glycation end-products (AGEs),Alzheimer’s disease (AD),Parkinson’s disease (PD),AGE-RAGE signaling, Protein misfolding, Oxidative stress, Neuroinflammation, Proteomics
[This article belongs to International Journal of Molecular Biotechnological Research (ijmbr)]
MOHAMMAD NADEEM KHAN. Non-Enzymatic Glycation in Alzheimer’s and Parkinson’s disease: A Molecular Approach to Pathology and Recent Advances. International Journal of Molecular Biotechnological Research. 2024; 02(02):-.
MOHAMMAD NADEEM KHAN. Non-Enzymatic Glycation in Alzheimer’s and Parkinson’s disease: A Molecular Approach to Pathology and Recent Advances. International Journal of Molecular Biotechnological Research. 2024; 02(02):-. Available from: https://journals.stmjournals.com/ijmbr/article=2024/view=0
References
document.addEventListener(‘DOMContentLoaded’,function(){frmFrontForm.scrollToID(‘frm_container_ref_113793’);});Edit
1. Prince, M., Wimo, A., Guerchet, M., Ali, G. C., Wu, Y. T., & Prina, M. (2015). World Alzheimer Report 2015—The global impact of dementia: An analysis of prevalence, incidence, cost and trends. Alzheimer’s Disease International. 2. Ross, C. A., & Poirier, M. A. (2004). Protein aggregation and neurodegenerative disease. Nature Medicine, 10(S7), S10–S17. https://doi.org/10.1038/nm1066 3. Singh, R., Barden, A., Mori, T., & Beilin, L. (2014). Advanced glycation end-products: A review. Diabetologia, 44(2), 129–146. https://doi.org/10.1007/s001250000161 4. Rabbani, N., & Thornalley, P. J. (2018). Advanced glycation endproducts in the pathogenesis of chronic kidney disease. Kidney International, 93(4), 803–813. https://doi.org/10.1016/j.kint.2017.11.034 5. Ahmed, N. (2005). Advanced glycation endproducts—Role in pathology of diabetic complications. Diabetes Research and Clinical Practice, 67(1), 3–21. https://doi.org/10.1016/j.diabres.2004.09.004 6. Lue, L. F., Walker, D. G., Brachova, L., Beach, T. G., Rogers, J., Schmidt, A. M., & Stern, D. M. (2009). Involvement of microglial receptor for advanced glycation endproducts (RAGE) inAlzheimer’s disease: Identification of a cellular activation mechanism. Experimental Neurology, 171(1), 29–45. https://doi.org/10.1006/exnr.2001.7741. 7. Kuhla, B., Lüth, H. J., Haferburg, D., Boeck, K., Arendt, T., & Münch, G. (2005). Methylglyoxal, glyoxal, and their detoxification in Alzheimer’s disease. Annals of the New York Academy of Sciences, 1043(1), 211-216. https://doi.org/10.1196/annals.1333.024 8. Chen, K., Maley, J., Ralph, M., Shneider, B. L., & Krasna, M. J. (2010). Glycation increases amyloid-beta aggregation and contributes to Alzheimer’s disease pathology. Neurobiology of Aging, 31(7), 1025-1033. https://doi.org/10.1016/j.neurobiolaging.2009.09.008 9. Vicente Miranda, H., Szego, É. M., Oliveira, L. M., Breda, C., Darendelioglu, E., de Oliveira, R. M., … & Outeiro, T. F. (2017). Glycation potentiates α-synuclein-associated neurodegeneration in synucleinopathies. Brain, 140(5), 1399-1419. https://doi.org/10.1093/brain/awx056 10. Lüth, H. J., Münch, G., & Arendt, T. (2005). Aberrant glycosylation in Alzheimer’s disease: A pivotal role for brain oxidative stress. The European Journal of Neuroscience, 22(6), 1552-1564. https://doi.org/10.1111/j.1460-9568.2005.04364.x 11. Ott, C., Jacobs, K., Haucke, E., Navarrete Santos, A., Grune, T., & Simm, A. (2014). Role of advanced glycation end products in cellular signaling. Redox Biology, 2, 411-429. https://doi.org/10.1016/j.redox.2014.01.009 12. Walker, D. G., Lue, L. F., Serrano, G., & Beach, T. G. (2015). Gene expression profiling of amyloid-beta peptide-stimulated human post-mortem brain microglia. Scientific Reports, 5, 15444. https://doi.org/10.1038/srep15444 13. Dong, Y., Li, X., Cheng, J., Hou, L., Zhang, J., & Liu, Y. (2020). Neuroinflammation as a target for treatment of Parkinson’s disease. Neurochemical Research, 45(5), 1045-1056. https://doi.org/10.1007/s11064-020-02995-7 14. Zhang, Q., Ames, J. M., Smith, R. D., Baynes, J. W., & Metz, T. O. (2017). Mass spectrometric detection of early glycation products on human serum albumin. Analytical Chemistry, 79(5), 2556-2564. https://doi.org/10.1021/ac061919d 15. Poulsen, M. W., Hedegaard, R. V., Andersen, J. M., De Courten, B., Bügel, S., & Nielsen, J. (2013). Advanced glycation end products in food and their effects on health. European Journal of Clinical Nutrition, 67(8), 903-909. https://doi.org/10.1038/ejcn.2013.98 16. Nielsen, M. L., Savitski, M. M., Zubarev, R. A., & Schmid, M. (2015). Proteomic and structural analysis of glycated proteins. Journal of Proteome Research, 14(3), 1195-1203. https://doi.org/10.1021/pr5009713 17. Ahmed, N., Thornalley, P. J., & Rabbani, N. (2020). Protein glycation, oxidative stress and ageing. Biochemical Journal, 477(6), 1153-1162. https://doi.org/10.1042/BCJ20190455 18. Chen, J., Xu, H., Li, M., & Li, G. (2018). A novel molecular dynamics simulation for the interactions between amyloid-beta peptide and AGEs. Journal of Molecular Structure, 1160, 356-365. https://doi.org/10.1016/j.molstruc.2018.02.034 19. Thornalley, P. J., Rabbani, N., & Ahmed, N. (2021). Advances in therapeutic inhibition of advanced glycation end products. Biochemical Pharmacology, 189, 114240. https://doi.org/10.1016/j.bcp.2020.114240 20. Chen, J., Liu, Q., & Zhang, R. (2019). Inhibition of advanced glycation end-product formation as a strategy for managing neurodegeneration. Frontiers in Pharmacology, 10, 1072. https://doi.org/10.3389/fphar.2019.01072 21. Yan, S. D., & Schmidt, A. M. (2016). Receptor for advanced glycation end-products (RAGE) as a therapeutic target: Mapping the path forward. Neurotherapeutics, 13(2), 223-238. https://doi.org/10.1007/s13311-016-0405-2 22. Zhao, L., & Smith, M. A. (2018). RAGE and Alzheimer’s disease: Targets for therapeutic intervention. Aging and Disease, 9(5), 958-970. https://doi.org/10.14336/AD.2017.1105 23. Uribarri, J., Cai, W., Sandu, O., & Vlassara, H. (2015). Dietary advanced glycation end products and their role in health and disease. Advances in Nutrition, 6(4), 463-471. https://doi.org/10.3945/an.115.008433 24. Liu, S., Zhao, J., Li, X., & Wang, Y. (2020). Dietary polyphenols and their anti-glycation effects: Potential therapeutic roles in neurodegenerative diseases. Food Chemistry, 323, 126791. https://doi.org/10.1016/j.foodchem.2020.126791 25. Bennett, R. E., & Krishnamurthy, S. (2023). Advances in high-throughput screening for glycation-targeted therapies in neurodegenerative diseases. Current Neuropharmacology, 21(2), 189-202. https://doi.org/10.2174/1570159X216662301230928
| Volume | 02 |
| Issue | 02 |
| Received | 08/11/2024 |
| Accepted | 15/11/2024 |
| Published | 16/11/2024 |